EXPERIMENTAL APPROACH
We used four human ESCC cell lines, cell viability assay, cell cycle and
apoptosis assay, RT-PCR, Western blot, immunohistochemistry and ESCC
xenografts model to clarify the roles of the therapeutic effect and
mechanism of ixazomib in ESCC.